[A new prevention strategy against meningococcal disease: the menigococcus B vaccine].
The new anti-meningococcal vaccine contributes not only to fight against a severe condition like the meningococcal disease caused by meningococcus B, but also gives us a new tool: inverse vaccinology. This technique parts from the bases of the virtual knowledge of the microorganism's genome, knowing all the proteins that the pathogen is able to express on its surface. This allows us to predict the candidate antigens which are most likely to be used in a potential vaccine. After the selection of these candidates, the vaccines are studied first in animals and later in humans. All this research was successful for the anti-meningococcal vaccine candidate and has allowed to obtain, through inverse vaccinology, a 4CMenB vaccine, containing 4 protein components, obtained from the meningococcus B genome, with antigenic potential to induce immune response. This guaranties an appropriate protection without the possibility of reversion of the microorganism to cause the disease. This new finding and this new vaccine could significantly change the future of meningococcal disease worldwide.